Get the Stockscreener App
13.12
4.02%
-0.55
After Hours:
12.91
-0.21
-1.60%
Carlsmed Inc stock is traded at $13.12, with a volume of 76,984.
It is down -4.02% in the last 24 hours and down -3.53% over the past month.
Carlsmed Inc is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. It is focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of AI-enabled software solutions, and interbody implants that it custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments. The Company designs, manufactures, and markets aprevo, a comprehensive technology platform for spine fusion surgery procedures.
See More
Previous Close:
$13.67
Open:
$13.68
24h Volume:
76,984
Relative Volume:
0.61
Market Cap:
$348.74M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.16%
1M Performance:
-3.53%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.95
$13.68
1-Week Range:
$12.94
$14.78
52-Week Range:
$11.81
$16.20
Carlsmed Inc Stock (CARL) Company Profile
Name
Carlsmed Inc
Sector
Industry
Phone
858-295-9290
Address
1800 ASTON AVENUE, CARLSBAD
Compare CARL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARL
Carlsmed Inc
|
13.12 | 363.36M | 0 | 0 | 0 | 0.00 |
|
VEEV
Veeva Systems Inc
|
286.59 | 48.92B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
96.39 | 17.25B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
65.61 | 13.59B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
90.52 | 7.99B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.70 | 7.14B | 906.14M | -52.62M | 89.62M | -0.3621 |
Carlsmed Inc Stock (CARL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Initiated | BTIG Research | Buy |
| Aug-18-25 | Initiated | BofA Securities | Buy |
| Aug-18-25 | Initiated | Goldman | Buy |
| Aug-18-25 | Initiated | Piper Sandler | Overweight |
| Aug-18-25 | Initiated | Truist | Buy |
Carlsmed Inc Stock (CARL) Latest News
Earnings Preview: Carlsmed to Report Financial Results Post-market on August 28 - 富途牛牛
People moves: Michael Kaplan rejoins StandardAero as legal chief as Jenifer Kamocsay moves over to Carlsmed - | Governance Intelligence
Carlsmed names Jennifer Kamocsay as CLO and secretary - Medical Buyer
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - Orthopedics This Week
Carlsmed appoints Jenifer Kamocsay as chief legal officer By Investing.com - Investing.com Nigeria
Carlsmed appoints Jennifer Kamocsay as CLO, secretary - TipRanks
Carlsmed appoints Jenifer Kamocsay as chief legal officer - Investing.com India
Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary - GlobeNewswire Inc.
Carlsmed, Inc. Selected for Inclusion in Russell 2000 Index - 富途牛牛
Carlsmed joins Russell 2000 Index following Q3 IPO - MSN
Carlsmed announces inclusion in Russell 2000 Index - TipRanks
Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index - MarketScreener
AI-Powered Spine Surgery Innovator Carlsmed Joins $9T Russell 2000 Index Following Successful IPO - Stock Titan
AI medtech firm Carlsmed prices $100.5M IPO - MSN
AI medtech firm Carlsmed to sell 6.7M shares in IPO - MSN
Goldman Sachs highlights two high-potential stocks: AI marketing platform Braze (BRZE.US) and medical technology company Carlsmed (CARL.US), assigning them a 'Buy' rating. - 富途牛牛
Carlsmed initiated with Buy at Truist on business potential - MSN
Carlsmed Q2 2025 revenue up 99% to USD 12.1M - Medical Buyer
Carlsmed stock rating reiterated at Buy by Goldman Sachs on growth outlook - Investing.com Australia
Carlsmed, Inc.: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Carlsmed, Inc.: Strong Performance and Promising Growth Prospects with Upcoming Product Launch - TipRanks
UPDATECarlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed Reports Strong Growth in Q2 2025 Earnings - TipRanks
Carlsmed 2025 Q2 Earnings Strong Revenue Growth Despite Widening Net Loss - AInvest
Carlsmed: A High-Growth AI-Driven MedTech Play in Spine Surgery - AInvest
Earnings call transcript: Carlsmed’s Q2 2025 revenue surges, stock rises - Investing.com
Carlsmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Carlsmed reports second quarter 2025 financial results - MarketScreener
Carlsmed® Q2 2025 Financial Performance: Assessing Long-Term Growth Potential in the AI-Driven Spine Surgery Revolution - AInvest
CARLSMED, INC. SEC 10-Q Report - TradingView
Carlsmed® Reports Second Quarter 2025 Financial Results - The Manila Times
Carlsmed, Inc.'s Q2 2025 Performance and Strategic Momentum: A Disruptive Force in AI-Driven Spine Surgery - AInvest
99% Growth: AI Spine Surgery Pioneer Carlsmed Hits $12.1M Revenue, Expands into Cervical Procedures - Stock Titan
Carlsmed CARL 2025Q2 Earnings Preview Upside Potential on AI-Driven Spine Solutions - AInvest
Two AI Small Caps Nobody Noticed - Nanalyze
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Truist Securities initiates coverage on Carlsmed stock with Buy rating By Investing.com - Investing.com Australia
Why Is Carlsmed Stock Gaining Monday?Carlsmed (NASDAQ:CARL) - Benzinga
Truist Initiates Buy on Carlsmed with Focus on Business Growth Potential - AInvest
Carlsmed initiated with Buy at Truist on business potential (CARL) - Seeking Alpha
BofA Securities Initiates Coverage on Carlsmed With Buy Rating, $16 Price Target - MarketScreener
This Synaptics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Goldman Sachs Initiates Coverage on Carlsmed With Buy Rating, $19 Price Target - MarketScreener
Carlsmed initiated with a Buy at BTIG - TipRanks
Truist Securities initiates coverage on Carlsmed stock with Buy rating - Investing.com
Truist Initiates Carlsmed at Buy With $18 Price Target - MarketScreener
Piper Sandler initiates coverage on Carlsmed with an Overweight rating, PT of $18. - AInvest
Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium Valuation - TipRanks
Carlsmed stock initiated with Buy rating at BTIG on customized implant tech - Investing.com
Carlsmed Inc Stock (CARL) Financials Data
There is no financial data for Carlsmed Inc (CARL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Carlsmed Inc Stock (CARL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sidow Kevin | Director |
Jul 24 '25 |
Buy |
15.00 |
13,333 |
199,995 |
59,566 |
| Mittendorff Robert II | Director |
Jul 24 '25 |
Buy |
15.00 |
1,333,333 |
19,999,995 |
5,013,839 |
| ROOT JONATHAN D | Director |
Jul 24 '25 |
Buy |
15.00 |
466,666 |
6,999,990 |
483,999 |
| YOUNG PHILIP M | Director |
Jul 24 '25 |
Buy |
15.00 |
59,999 |
899,985 |
53,333 |
8.35%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):